Maze Therapeutics (NASDAQ:MAZE) Shares Up 5.5% After Better-Than-Expected Earnings

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) shot up 5.5% on Thursday following a better than expected earnings announcement. The company traded as high as $33.44 and last traded at $33.4720. 464,133 shares changed hands during trading, a decline of 28% from the average session volume of 640,987 shares. The stock had previously closed at $31.73.

The company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08.

Maze Therapeutics News Roundup

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Maze announced positive topline Phase 2 HORIZON results for MZE829 showing clinically meaningful uACR reductions (35.6% mean reduction in broad AMKD at week 12; stronger reductions in FSGS and non‑diabetic subgroups) and said it will advance MZE829 into a pivotal program — a clear de‑risking milestone for a lead asset. Maze Announces Positive Topline Data
• Positive Sentiment: Analysts reacted with bullish calls and higher targets — HC Wainwright raised its price target to $110 and BTIG reaffirmed a buy with a $46 target — supporting upside expectations if pivotal plans succeed. Analyst Upgrades
• Positive Sentiment: Quarterly results: Maze beat consensus EPS (reported ($0.65) vs. ($0.73) est.) and reiterated a strong cash position (~$360M), which management says funds operations into 2028 — reduces near‑term financing risk. Q4 and FY2025 Report
• Neutral Sentiment: Corporate governance update: Neil Kumar (BridgeBio founder/CEO) joined Maze’s board — signal of industry expertise but longer‑term impact on strategy is uncertain. Board Addition
• Negative Sentiment: Several outlets described the Phase 2 readout as “mixed” and reported a near‑one‑third drop in market cap as investors parsed subgroup vs overall results and durability/clinical design questions — headline framing triggered aggressive profit‑taking. Mixed Midstage Data Coverage
• Negative Sentiment: An executive disclosed a ~$736K insider sale (15,000 shares via option exercise) reported March 20 — such filings can amplify selling pressure during volatile moves even if routine. Insider Sale Report
• Negative Sentiment: Johnson Fistel announced an investigation into potential claims against Maze executives related to investor losses — legal scrutiny can prolong volatility and increase perceived risk. Shareholder Investigation Notice

Analyst Ratings Changes

Several research firms have commented on MAZE. HC Wainwright increased their price objective on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday. Wedbush boosted their target price on shares of Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a report on Monday, March 16th. BTIG Research restated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday. Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Finally, Lifesci Capital upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $64.11.

Insider Activity at Maze Therapeutics

In related news, insider Atul Dandekar sold 7,500 shares of the firm’s stock in a transaction on Thursday, January 29th. The stock was sold at an average price of $44.27, for a total value of $332,025.00. Following the completion of the sale, the insider directly owned 10,503 shares in the company, valued at $464,967.81. This trade represents a 41.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Harold Bernstein sold 15,000 shares of Maze Therapeutics stock in a transaction on Friday, March 20th. The stock was sold at an average price of $49.10, for a total transaction of $736,500.00. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 245,000 shares of company stock worth $10,504,792.

Hedge Funds Weigh In On Maze Therapeutics

Large investors have recently made changes to their positions in the company. Ensign Peak Advisors Inc purchased a new stake in Maze Therapeutics in the 2nd quarter worth about $227,000. Frazier Life Sciences Management L.P. boosted its position in shares of Maze Therapeutics by 10.6% during the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after buying an additional 438,274 shares during the period. Washington University bought a new position in shares of Maze Therapeutics during the third quarter valued at approximately $5,463,000. ArrowMark Colorado Holdings LLC bought a new position in shares of Maze Therapeutics during the third quarter valued at approximately $14,135,000. Finally, Virtus Investment Advisers LLC purchased a new stake in shares of Maze Therapeutics in the second quarter worth approximately $85,000.

Maze Therapeutics Price Performance

The stock has a market capitalization of $1.53 billion, a PE ratio of -9.82 and a beta of 4.47. The firm has a fifty day moving average price of $45.81 and a two-hundred day moving average price of $37.51.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.